GB9226111D0 - Madicaments - Google Patents

Madicaments

Info

Publication number
GB9226111D0
GB9226111D0 GB929226111A GB9226111A GB9226111D0 GB 9226111 D0 GB9226111 D0 GB 9226111D0 GB 929226111 A GB929226111 A GB 929226111A GB 9226111 A GB9226111 A GB 9226111A GB 9226111 D0 GB9226111 D0 GB 9226111D0
Authority
GB
United Kingdom
Prior art keywords
madicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929226111A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GB929226111A priority Critical patent/GB9226111D0/en
Publication of GB9226111D0 publication Critical patent/GB9226111D0/en
Priority to PCT/EP1993/003473 priority patent/WO1994013291A1/fr
Priority to AU56983/94A priority patent/AU5698394A/en
Priority to JP6513782A priority patent/JPH08504419A/ja
Priority to EP94902735A priority patent/EP0674514A1/fr
Priority to ZA939317A priority patent/ZA939317B/xx
Priority to CN93112828A priority patent/CN1091636A/zh
Priority to MX9307946A priority patent/MX9307946A/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GB929226111A 1992-12-15 1992-12-15 Madicaments Pending GB9226111D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GB929226111A GB9226111D0 (en) 1992-12-15 1992-12-15 Madicaments
PCT/EP1993/003473 WO1994013291A1 (fr) 1992-12-15 1993-12-07 Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle
AU56983/94A AU5698394A (en) 1992-12-15 1993-12-07 Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives
JP6513782A JPH08504419A (ja) 1992-12-15 1993-12-07 カルシウムチャンネル拮抗薬としてのアリールオキシアルキル置換環状アミンの使用および新規フェニルオキシアルキルピペリジン誘導体
EP94902735A EP0674514A1 (fr) 1992-12-15 1993-12-07 Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle
ZA939317A ZA939317B (en) 1992-12-15 1993-12-13 Medicament
CN93112828A CN1091636A (zh) 1992-12-15 1993-12-14 药物
MX9307946A MX9307946A (es) 1992-12-15 1993-12-14 Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929226111A GB9226111D0 (en) 1992-12-15 1992-12-15 Madicaments

Publications (1)

Publication Number Publication Date
GB9226111D0 true GB9226111D0 (en) 1993-02-10

Family

ID=10726633

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929226111A Pending GB9226111D0 (en) 1992-12-15 1992-12-15 Madicaments

Country Status (8)

Country Link
EP (1) EP0674514A1 (fr)
JP (1) JPH08504419A (fr)
CN (1) CN1091636A (fr)
AU (1) AU5698394A (fr)
GB (1) GB9226111D0 (fr)
MX (1) MX9307946A (fr)
WO (1) WO1994013291A1 (fr)
ZA (1) ZA939317B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314973D0 (en) * 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
GB9411052D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Medicaments
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
AU2982595A (en) * 1994-07-14 1996-02-16 Smithkline Beecham Plc Benzocycloalkylamine derivatives as calcium chanel antagonists
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
EP0790235A1 (fr) * 1996-02-15 1997-08-20 Sankyo Company Limited Dérivés de diaryle-alkanes contenant un groupe alicyclique, leur préparation et leurs applications thérapeutiques et prophylactiques
US6110937A (en) 1997-04-03 2000-08-29 Syntex Usa, Inc. Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain
CA2232147A1 (fr) * 1997-04-03 1998-10-03 F. Hoffmann-La Roche Ag Derives de la phenoxymethylpiperidine
US6251919B1 (en) 1998-02-27 2001-06-26 Warner-Lambert Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
ES2233493T3 (es) * 1999-12-21 2005-06-16 Mitsubishi Pharma Corporation Agentes terapeuticos y/o profilacticos para trastornos del sistema nervioso.
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
EP1318988A2 (fr) 2000-09-11 2003-06-18 Sepracor, Inc. Ligands pour les recepteurs de monoamine et transporteurs, et procedes d'utilisation de ces derniers (neurotransmission)
WO2004078715A1 (fr) 2003-03-07 2004-09-16 Astellas Pharma Inc. Derive heterocyclique azote contenant du styryl 2,6-disubstitue
US7521462B2 (en) 2004-02-27 2009-04-21 Eli Lilly And Company 4-Amino-piperidine derivatives as monoamine uptake inhibitors
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
NZ566788A (en) 2005-09-21 2012-10-26 Decode Genetics Ehf Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
WO2007073407A1 (fr) * 2005-12-21 2007-06-28 Decode Genetics Ehf Inhibiteurs heterocycliques de lta4h a substitution biaryl, contenant de l'azote, destines au traitement d'inflammations
US10772858B2 (en) 2015-05-01 2020-09-15 Georgia State University Research Foundation, Inc. Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1096441A (en) * 1964-01-15 1967-12-29 Bristol Myers Co Ethers of benzyl phenols and a process for the preparation thereof
US3381013A (en) * 1964-01-15 1968-04-30 Bristol Myers Co Heterocyclicamino ethers of benzylphenols
GB1203149A (en) * 1968-06-10 1970-08-26 Ici Ltd Piperidine derivatives
GB1319252A (en) * 1969-06-05 1973-06-06 Ciba Geigy Ag 1-phenyl-alkanols and process for making same
DE2728898A1 (de) * 1977-06-27 1979-01-18 Thomae Gmbh Dr K Neue morpholinderivate
DE2811952A1 (de) * 1978-03-18 1979-10-31 Merck Patent Gmbh Phenoxyalkylamine und verfahren zu ihrer herstellung
FR2443246A1 (fr) * 1978-12-05 1980-07-04 Pharmindustrie Nouveaux medicaments a base de derives de la phenyl-1 (piperidyl-4)-3 propanone-1
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
US4822778A (en) * 1988-01-19 1989-04-18 Gunnar Aberg Membrane stabilizing phenoxy-piperidine compounds and pharmaceutical compositions employing such compounds
US5169855A (en) * 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
IE912760A1 (en) * 1990-08-06 1992-02-12 Smith Kline French Lab Compounds
IE912759A1 (en) * 1990-08-06 1992-02-12 Smith Kline French Lab Compounds
GB9113031D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
JPH07503461A (ja) * 1992-01-28 1995-04-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー カルシウムチャンネル拮抗薬としての化合物

Also Published As

Publication number Publication date
MX9307946A (es) 1994-08-31
JPH08504419A (ja) 1996-05-14
WO1994013291A1 (fr) 1994-06-23
EP0674514A1 (fr) 1995-10-04
CN1091636A (zh) 1994-09-07
AU5698394A (en) 1994-07-04
ZA939317B (en) 1995-06-13

Similar Documents

Publication Publication Date Title
DE69307690D1 (en) Implantierbare penis-prothese
DE69319731D1 (en) Wässrige polyurethan-dispersionen
GB2269063B (en) Auto-reclosers
AU115931S (en) Cuff-link
GB2267325B (en) Autotensioner
DE59302394D1 (en) Linearlagerelement
DE69306746D1 (en) Schlichtmittelzusammensetzung
EP0563714A3 (en) Tnf-muteins
GB2264893B (en) Workcentre
GB9226111D0 (en) Madicaments
EP0556141A3 (en) Air-filtration-module
AU116869S (en) Bottle-cooler
DE69327712D1 (en) Custardkreme
DE69318966D1 (en) Chemilumineszenzverstärker
DE69321365D1 (en) Polyacetalharzzusammensetzung
DE69315037D1 (en) Phasendifferenz-kompensationsfilm
GB2268224B (en) Letterplates
GB9200100D0 (en) Hub-lock
EP0586950A3 (en) Seeddrill
GB2267494B (en) Trisamidodithionodiphosphates
EP0555626A3 (en) Coinchecker
GB2269580B (en) Palletainers
GB9200019D0 (en) Workhoist
GB2266446B (en) Litterbins
GB2271600B (en) Cord-lock